Page last updated: 2024-12-10

chaetomellic acid a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chaetomellic acid A: structure given in first source; an inhibitor of farnesyl-protein transferase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3037595
CHEMBL ID103955
MeSH IDM0215234

Synonyms (7)

Synonym
chaetomellic acid a
CHEMBL103955 ,
(z)-2-methyl-3-tetradecylbut-2-enedioic acid
bdbm50059863
(z)-2-methyl-3-tetradecyl-but-2-enedioic acid
2-butenedioic acid, 2-methyl-3-tetradecyl-, (z)-
148796-51-4

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)IC50 (µMol)15.44170.00050.471610.0000AID1173431; AID1313127; AID460101; AID711540; AID73120; AID74643
Protein farnesyltransferase subunit betaHomo sapiens (human)IC50 (µMol)0.13000.00050.21772.5000AID1173431; AID1313127; AID460101; AID711540; AID73120
Geranylgeranyl transferase type-1 subunit betaHomo sapiens (human)IC50 (µMol)92.00000.00732.364210.0000AID74643
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
transforming growth factor beta receptor signaling pathwayProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of Rac protein signal transductionProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of tubulin deacetylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of deacetylase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
lipid metabolic processProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase subunit betaHomo sapiens (human)
protein geranylgeranylationGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
Rab geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
receptor tyrosine kinase bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
alpha-tubulin bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
molecular adaptor activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
zinc ion bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
protein geranylgeranyltransferase activityGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
protein bindingGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
zinc ion bindingGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytosolProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
plasma membraneProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytoplasmProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytosolProtein farnesyltransferase subunit betaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase subunit betaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase complexGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1659668Inhibition of C-terminal His6-tagged human recombinat FTase expressed in Escherichia coli BL21 RIL (DE3) cells using Dansyl-GCVLS peptide and farnesyl pyrophosphate as substrate at 100 uM measured for 15 mins by fluorimetric analysis relative to control2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Ultrasounds-mediated 10-seconds synthesis of chalcones as potential farnesyltransferase inhibitors.
AID460101Inhibition of human recombinant FTase by fluorescent-based assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Towards the synthesis of bisubstrate inhibitors of protein farnesyltransferase: Synthesis and biological evaluation of new farnesylpyrophosphate analogues.
AID1313127Inhibition of human recombinant farnesyltransferase using farnesylpyrophosphate and dansyl-GCVLS as substrate measured for 15 mins by fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
New indolizine-chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation.
AID711540Inhibition of human FTPase2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID1659669Inhibition of C-terminal His6-tagged human recombinat FTase expressed in Escherichia coli BL21 RIL (DE3) cells using Dansyl-GCVLS peptide and farnesyl pyrophosphate as substrate measured for 15 mins by fluorimetric analysis2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Ultrasounds-mediated 10-seconds synthesis of chalcones as potential farnesyltransferase inhibitors.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID74933In vitro inhibition of geranylgeranyl-protein transferase type-II2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Cyclic acid anhydrides as a new class of potent, selective and non-peptidic inhibitors of geranylgeranyl transferase.
AID74643In vitro inhibition of geranylgeranyl-protein transferase type-I2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Cyclic acid anhydrides as a new class of potent, selective and non-peptidic inhibitors of geranylgeranyl transferase.
AID73120Activity against human Farnesyltransferase1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Ras farnesyltransferase: a new therapeutic target.
AID1313126Inhibition of human recombinant farnesyltransferase using farnesylpyrophosphate and dansyl-GCVLS as substrate at 100 uM measured for 15 mins by fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
New indolizine-chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation.
AID1173431Inhibition of human recombinant farnesyltransferase using octyl-beta-D-glucopyranoside as substrate after 15 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Novel indolizine derivatives with unprecedented inhibitory activity on human farnesyltransferase.
AID1173430Inhibition of human recombinant farnesyltransferase using octyl-beta-D-glucopyranoside as substrate at 100 uM after 15 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Novel indolizine derivatives with unprecedented inhibitory activity on human farnesyltransferase.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID460100Inhibition of yeast recombinant FTase by fluorescent-based assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Towards the synthesis of bisubstrate inhibitors of protein farnesyltransferase: Synthesis and biological evaluation of new farnesylpyrophosphate analogues.
AID1712054Inhibition of bovine brain FTase using 3H-farnesyl diphosphate as substrate incubated for 30 mins by beta-plate counting method2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Discovery and preliminary structure-activity relationship studies on tecomaquinone I and tectol as novel farnesyltransferase and plasmodial inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (19.05)18.2507
2000's8 (38.10)29.6817
2010's8 (38.10)24.3611
2020's1 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.44 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]